Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma

Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morb...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 2012-07, Vol.130 (1), p.e243-e247
Main Authors: Demir, Haci Ahmet, Ekici, Filiz, Yazal Erdem, Arzu, Emir, Suna, Tunç, Bahattin
Format: Article
Language:English
Subjects:
Cardiovascular disease
Care and treatment
Diagnosis
Everolimus
Heart Neoplasms - congenital
Heart Neoplasms - diagnosis
Heart Neoplasms - drug therapy
Humans
Infant mortality
Infant, Newborn
Male
Newborn babies
Pediatrics
Protein Kinase Inhibitors - therapeutic use
Rhabdomyolysis
Rhabdomyoma - congenital
Rhabdomyoma - diagnosis
Rhabdomyoma - drug therapy
Risk factors
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c427t-e38ee51e52aa1c3df1b2387a44749371e05355cd6c4366cb69aad3545cf4ca3d3
cites cdi_FETCH-LOGICAL-c427t-e38ee51e52aa1c3df1b2387a44749371e05355cd6c4366cb69aad3545cf4ca3d3
container_end_page e247
container_issue 1
container_start_page e243
container_title Pediatrics (Evanston)
container_volume 130
creator Demir, Haci Ahmet
Ekici, Filiz
Yazal Erdem, Arzu
Emir, Suna
Tunç, Bahattin
description Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment.
doi_str_mv 10.1542/peds.2011-3476
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023294404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A300917477</galeid><sourcerecordid>A300917477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-e38ee51e52aa1c3df1b2387a44749371e05355cd6c4366cb69aad3545cf4ca3d3</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhkVpaTZprz0WQS-5eKtPa91bWNIPCOTS3AJiLI-9DrK1leSQ_PvIbNpDT3OYZ15e5iHkE2dbrpX4esQubQXjvJLK1G_IhrNmVylh9FuyYUzySjGmz8h5Sg-MMaWNeE_OhDBScNNsyP31I8bgx2lJ3yhQdwDvcR7GeaBdXAY6zjQfkOaIkCecMw09nRafxz448GUdjhih9UgdxG4ER-MB2i5Mz2GCD-RdDz7hx9d5Qe6-X__e_6xubn_82l_dVK4UzRXKHaLmqAUAd7LreSvkzoBSRjXScGRaau262ilZ166tG4BOaqVdrxzITl6Qy1PuMYY_C6ZspzE59B5mDEuynAkpGqWYKuiX_9CHsMS5tFsppfhOsKZQ1YkawKMdZxfmjE_ZhfKcAW0pv7-1V5KxhhtlTOG3J97FkFLE3h7jOEF8LqF29WRXT3b1ZFdP5eDza42lnbD7h_8VI18A0UCNfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1024418209</pqid></control><display><type>article</type><title>Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma</title><source>EZB Electronic Journals Library</source><creator>Demir, Haci Ahmet ; Ekici, Filiz ; Yazal Erdem, Arzu ; Emir, Suna ; Tunç, Bahattin</creator><creatorcontrib>Demir, Haci Ahmet ; Ekici, Filiz ; Yazal Erdem, Arzu ; Emir, Suna ; Tunç, Bahattin</creatorcontrib><description>Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2011-3476</identifier><identifier>PMID: 22732179</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>United States: American Academy of Pediatrics</publisher><subject>Cardiovascular disease ; Care and treatment ; Diagnosis ; Everolimus ; Heart Neoplasms - congenital ; Heart Neoplasms - diagnosis ; Heart Neoplasms - drug therapy ; Humans ; Infant mortality ; Infant, Newborn ; Male ; Newborn babies ; Pediatrics ; Protein Kinase Inhibitors - therapeutic use ; Rhabdomyolysis ; Rhabdomyoma - congenital ; Rhabdomyoma - diagnosis ; Rhabdomyoma - drug therapy ; Risk factors ; Sirolimus - analogs &amp; derivatives ; Sirolimus - therapeutic use ; Tumors</subject><ispartof>Pediatrics (Evanston), 2012-07, Vol.130 (1), p.e243-e247</ispartof><rights>Copyright American Academy of Pediatrics Jul 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-e38ee51e52aa1c3df1b2387a44749371e05355cd6c4366cb69aad3545cf4ca3d3</citedby><cites>FETCH-LOGICAL-c427t-e38ee51e52aa1c3df1b2387a44749371e05355cd6c4366cb69aad3545cf4ca3d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22732179$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Demir, Haci Ahmet</creatorcontrib><creatorcontrib>Ekici, Filiz</creatorcontrib><creatorcontrib>Yazal Erdem, Arzu</creatorcontrib><creatorcontrib>Emir, Suna</creatorcontrib><creatorcontrib>Tunç, Bahattin</creatorcontrib><title>Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment.</description><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Everolimus</subject><subject>Heart Neoplasms - congenital</subject><subject>Heart Neoplasms - diagnosis</subject><subject>Heart Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Infant mortality</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Newborn babies</subject><subject>Pediatrics</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Rhabdomyolysis</subject><subject>Rhabdomyoma - congenital</subject><subject>Rhabdomyoma - diagnosis</subject><subject>Rhabdomyoma - drug therapy</subject><subject>Risk factors</subject><subject>Sirolimus - analogs &amp; derivatives</subject><subject>Sirolimus - therapeutic use</subject><subject>Tumors</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNpdkU1r3DAQhkVpaTZprz0WQS-5eKtPa91bWNIPCOTS3AJiLI-9DrK1leSQ_PvIbNpDT3OYZ15e5iHkE2dbrpX4esQubQXjvJLK1G_IhrNmVylh9FuyYUzySjGmz8h5Sg-MMaWNeE_OhDBScNNsyP31I8bgx2lJ3yhQdwDvcR7GeaBdXAY6zjQfkOaIkCecMw09nRafxz448GUdjhih9UgdxG4ER-MB2i5Mz2GCD-RdDz7hx9d5Qe6-X__e_6xubn_82l_dVK4UzRXKHaLmqAUAd7LreSvkzoBSRjXScGRaau262ilZ166tG4BOaqVdrxzITl6Qy1PuMYY_C6ZspzE59B5mDEuynAkpGqWYKuiX_9CHsMS5tFsppfhOsKZQ1YkawKMdZxfmjE_ZhfKcAW0pv7-1V5KxhhtlTOG3J97FkFLE3h7jOEF8LqF29WRXT3b1ZFdP5eDza42lnbD7h_8VI18A0UCNfw</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Demir, Haci Ahmet</creator><creator>Ekici, Filiz</creator><creator>Yazal Erdem, Arzu</creator><creator>Emir, Suna</creator><creator>Tunç, Bahattin</creator><general>American Academy of Pediatrics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma</title><author>Demir, Haci Ahmet ; Ekici, Filiz ; Yazal Erdem, Arzu ; Emir, Suna ; Tunç, Bahattin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-e38ee51e52aa1c3df1b2387a44749371e05355cd6c4366cb69aad3545cf4ca3d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Everolimus</topic><topic>Heart Neoplasms - congenital</topic><topic>Heart Neoplasms - diagnosis</topic><topic>Heart Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Infant mortality</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Newborn babies</topic><topic>Pediatrics</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Rhabdomyolysis</topic><topic>Rhabdomyoma - congenital</topic><topic>Rhabdomyoma - diagnosis</topic><topic>Rhabdomyoma - drug therapy</topic><topic>Risk factors</topic><topic>Sirolimus - analogs &amp; derivatives</topic><topic>Sirolimus - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Demir, Haci Ahmet</creatorcontrib><creatorcontrib>Ekici, Filiz</creatorcontrib><creatorcontrib>Yazal Erdem, Arzu</creatorcontrib><creatorcontrib>Emir, Suna</creatorcontrib><creatorcontrib>Tunç, Bahattin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Demir, Haci Ahmet</au><au>Ekici, Filiz</au><au>Yazal Erdem, Arzu</au><au>Emir, Suna</au><au>Tunç, Bahattin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>130</volume><issue>1</issue><spage>e243</spage><epage>e247</epage><pages>e243-e247</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment.</abstract><cop>United States</cop><pub>American Academy of Pediatrics</pub><pmid>22732179</pmid><doi>10.1542/peds.2011-3476</doi></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 2012-07, Vol.130 (1), p.e243-e247
issn 0031-4005
1098-4275
language eng
recordid cdi_proquest_miscellaneous_1023294404
source EZB Electronic Journals Library
subjects Cardiovascular disease
Care and treatment
Diagnosis
Everolimus
Heart Neoplasms - congenital
Heart Neoplasms - diagnosis
Heart Neoplasms - drug therapy
Humans
Infant mortality
Infant, Newborn
Male
Newborn babies
Pediatrics
Protein Kinase Inhibitors - therapeutic use
Rhabdomyolysis
Rhabdomyoma - congenital
Rhabdomyoma - diagnosis
Rhabdomyoma - drug therapy
Risk factors
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Tumors
title Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T17%3A15%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Everolimus:%20a%20challenging%20drug%20in%20the%20treatment%20of%20multifocal%20inoperable%20cardiac%20rhabdomyoma&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Demir,%20Haci%20Ahmet&rft.date=2012-07-01&rft.volume=130&rft.issue=1&rft.spage=e243&rft.epage=e247&rft.pages=e243-e247&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2011-3476&rft_dat=%3Cgale_proqu%3EA300917477%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c427t-e38ee51e52aa1c3df1b2387a44749371e05355cd6c4366cb69aad3545cf4ca3d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1024418209&rft_id=info:pmid/22732179&rft_galeid=A300917477&rfr_iscdi=true